Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    cerulean
Show Display Options
Rank Status Study
1 Unknown  CRLX101 Plus Bevacizumab in Advanced RCC
Condition: Renal Cell Carcinoma
Interventions: Drug: CRLX101 (Cerulean);   Drug: Bevacizumab
2 Active, not recruiting A Phase 2 Study of CRLX101 in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: CRLX101;   Other: Best Supportive Care
3 Recruiting CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: CRLX101 + bevacizumab;   Drug: sorafenib / everolimus / pazopanib / axitinib / bevacizumab / sunitinib / other approved drug
4 Recruiting Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
Condition: Rectal Cancer
Interventions: Drug: CRLX101;   Drug: Capecitabine;   Radiation: Radiotherapy;   Procedure: Surgery
5 Withdrawn Efficacy Study of Maintenance Therapy for Ovarian Cancer Patients
Conditions: Cancer;   Ovarian Cancer;   Solid Tumor
Interventions: Drug: IT-101;   Drug: 5% Dextrose (Placebo)
6 Terminated Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
Conditions: Cancer;   Ovarian Cancer;   Solid Tumor
Interventions: Drug: IT-101 (12mg/m2/dose);   Drug: IT-101 (15mg/m2/dose);   Drug: 5% Dextrose (Placebo)
7 Completed Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors
Conditions: Cancer;   Solid Tumor
Intervention: Drug: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer

Indicates status has not been verified in more than two years